Heung-moon M. Chang
Seoul, Republic of Korea
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 55 publications
Predicting Chemotherapy Response in Patients With Advanced or Metastatic Pancreatic Cancer Using Machine Learning.
Journal: JCO clinical cancer informatics
Published: December 02, 2025
Zanidatamab in HER2-Positive Metastatic Biliary Tract Cancer: Final Results From HERIZON-BTC-01.
Journal: JAMA oncology
Published: November 20, 2025
A Phase II Trial of Pemetrexed Plus Oxaliplatin in Patients With Advanced Biliary Tract Cancer After Failure of Gemcitabine Plus Cisplatin-based Chemotherapy.
Journal: Anticancer research
Published: June 10, 2025
A plain language summary of the results from the phase 2b HERIZON-BTC-01 study of zanidatamab in participants with HER2-amplified biliary tract cancer.
Journal: Future oncology (London, England)
Published: August 08, 2024
Plain language summary of the FOENIX-CCA2 study: futibatinib for people with advanced bile duct cancer.
Journal: Future oncology (London, England)
Published: June 17, 2024
Metabolic tumor burden as a prognostic indicator after neoadjuvant chemotherapy in pancreatic cancer.
Journal: International journal of surgery (London, England)
Published: December 20, 2023
Efficacy and Safety of Lu-177 DOTATATE Peptide Receptor Radionuclide Therapy in Patients with Unresectable or Metastatic Neuroendocrine Tumors in Korea.
Journal: Targeted oncology
Published: November 28, 2023
Clinical Outcomes of Surgery after Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Ductal Adenocarcinoma.
Journal: Cancer research and treatment
Published: August 28, 2023
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
Journal: The Lancet. Oncology
Published: March 30, 2023
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
Journal: The New England journal of medicine
Published: January 18, 2023
Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 15, 2022
Last Updated: 09/26/2026